Brett joined Foresite Capital in 2015 with more than 15 years of healthcare private equity and consulting experience. Prior to joining Foresite, Brett was a Partner at Aisling Capital, a life sciences-dedicated venture capital and private equity firm that also manages the investments of the Perseus-Soros Bio Pharmaceutical Fund. Over the course of more than a decade at Aisling Capital, Brett served as a member of the Board of Directors of Aragon Pharmaceuticals, Seragon Pharmaceuticals and Planet Biopharmaceuticals, and as a board observer at Catalent Pharma Solutions, among other companies. Previously, Brett was an Associate Principal at McKinsey & Company and a senior member of the Pharmaceuticals and Medical Products practice. While at McKinsey, he worked closely with management of large pharmaceutical companies based in the U.S., Europe and Japan. His work focused on pharmaceutical/biotech alliances, product launch planning, product growth strategy and market assessments across multiple therapeutic areas. Brett is a member of the Oversight Committee for the Technology Development Fund at Memorial Sloan Kettering Cancer Center in New York City. He also serves as a member of the Strategic Portfolio Optimization Committee at the City of Hope National Medical Center in Duarte, CA. He is a life member of the Council on Foreign Relations. Brett received his M.D. from Harvard Medical School and graduated Yale magna cum laude with Distinctions in English, Molecular Biophysics, and Biochemistry.